BodyWorks Eve installed at NYU School of Medicine
MedaPhor Group plc
("MedaPhor" or the "Group" or the "Company")
First BodyWorks Eve installed at NYU School of Medicine
MedaPhor, the intelligent ultrasound software and simulation company, announces that it has installed its first BodyWorks Eve, Point of Care ultrasound (PoCUS) simulator, at NYU School of Medicine, in the simulation laboratory of the affiliated Veterans Affairs New York Harbor Healthcare System NY Campus, New York, USA.
BodyWorks Eve is an ultra-realistic female manikin-based simulator designed specifically for doctors
looking to train in Point of Care Ultrasound (PoCUS)and will aid the teaching of PoCUS to medical students, residents and faculty.
Complete with over 100 real patient scans and over 10,000 pathology variations across cardiac, lung, transabdominal and pelvic ultrasound, it is the most dynamic simulator available for ultrasound scenario training with structured educational content, based on the International Federation of Emergency Medicine (IFEM) PoCUS curriculum guidelines.
Dr. Brian Kaufman, Professor of Medicine, Anesthesiology, Neurology and Neurosurgery and Director of the simulation laboratory at the VA, commented:
"It's our role as a University to ensure that our medical students, residents and faculty are armed with the knowledge and practical skills needed to be the best physicians they can be as they embark on or continue their medical careers.
'Ultrasound is growing exponentially, and we are confident that integrating BodyWorks Eve into our PoCUS curriculum will enable us to deliver the best possible educational outcomes for our learners."
Ian Whittaker, Chief Operating Officer, at MedaPhor, said:
"BodyWorks Eve has gained great market acceptance and customer feedback since its recent launch. NYU is the first in a long line of customers who are looking to deploy BodyWorks Eve to advance their PoCUS training capabilities and reap the educational benefits of a truly one-of-a-kind ultrasound simulator."
|
MedaPhor Group plc |
||
|
Stuart Gall, CEO Ian Whittaker, COO |
Tel: +44 (0)29 2075 6534 |
|
|
|
|
|
|
Cenkos Securities |
Tel: +44 (0)20 7397 8900 |
|
|
Camilla Hume (Nominated Advisor) |
|
|
|
Michael Johnson / Julian Morse (Corporate Broking) |
|
|
|
|
|
|
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 or medaphor@walbrookpr.com |
|
|
Paul McManus / Anna Dunphy |
Mob: +44 (0)7980 541 893 / Mob: +44 (0)7876 741 001 |
|
About MedaPhor (www.investors.medaphor.com)
MedaPhor (AIM: MED), the intelligent ultrasound software and simulation company, develops artificial intelligence-based clinical image analysis software tools, augmented reality-based needle guidance software and advanced hi-fidelity haptic and manikin-based training simulators for medical practitioners.
Based in Cardiff and Oxford in the UK, Atlanta in the US and Hong Kong in Asia, MedaPhor operates two divisions:
Intelligent Ultrasound Simulation Division
Focuses on hi-fidelity ultrasound education and training through simulation. Its three main products are the ScanTrainer OBGYN and General Medical simulator training platform, the HeartWorks echocardiography simulator platform and the BodyWorks Eve Point of Care and Emergency Medicine Simulator. Over 500 MedaPhor simulators have been sold to over 300 medical institutions in over 30 countries around the world.
Intelligent Ultrasound Clinical Division
Focuses on augmented reality and deep-learning based algorithms to make ultrasound machines smarter and more accessible. Products in development include ScanNav and NeedleGuide. ScanNav uses machine-learning based algorithms to automatically identify, grade and capture good ultrasound images. NeedleGuide aims to simplify ultrasound-guided needling by using deep learning and augmented reality to provide the user with pathway guidance and automated tracking for a range of medical procedures.
Some products in the pipeline may require US FDA approval, as such this material should be considered informational only and does not constitute an offer to sell or infer claims or benefits.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund